8-K ·Filed Feb 27, 2026

CI

Cigna Group
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001140361-26-007049
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The reaffirmation of guidance suggests confidence in current business performance, but provides no new information or upward revision that would signal improved fundamentals. Traders should monitor upcoming earnings reports for confirmation of this outlook.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
CI ▼ -2.96% at T+60d
NEUTRAL call ✗ call lost -2.96% · α vs SPY -12.35% · entry $289.40 → $280.83
Entry anchored
Feb 26, 03:59 PM ET
via exchange tick
T+1d
+0.43%
call +0.43% · α +0.37%
$290.64
settled 7mo ago
T+5d
-6.34%
call -6.34% · α -4.36%
$271.04
settled 7mo ago
T+20d
-9.51%
call -9.51% · α -1.95%
$261.89
settled 6mo ago
T+60d
-2.96%
call -2.96% · α -12.35%
$280.83
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

The Cigna Group reaffirmed its full-year 2026 guidance, projecting consolidated adjusted income from operations of at least $30.25 per share. This outlook was previously disclosed on February 5, 2026, and is being reiterated during investor meetings.

Key Facts

  • Cigna reaffirmed its 2026 full-year outlook for adjusted income from operations of at least $30.25 per share
  • The guidance was originally provided on February 5, 2026, and is being reiterated in upcoming investor meetings
  • Adjusted income from operations excludes net investment gains/losses, amortization of acquired intangible assets, and special items
  • The company cannot provide a reconciliation to GAAP net income due to uncertainty around future investment results and special items

Financial Impact

Projected adjusted income from operations of at least $30.25 per share for 2026

eps

Risk Factors

  • Adjusted income is a non-GAAP measure and may not reflect actual GAAP earnings performance
  • Inability to reconcile guidance to GAAP net income due to unpredictable investment results and special items
  • Healthcare cost trends, regulatory changes, or pricing pressures could impact the company's ability to achieve the projected results

Market Snapshot

Exchange
NYSE

Investment Themes

Traditional Finance

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-007049
Document: 0001140361-26-007049-index-headers.html0001140361-26-007049
Document: 0001140361-26-007049-index.html0001140361-26-007049
Document: 0001140361-26-007049.txt0001140361-26-007049
10 reports for CI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CI — sortable, filterable
TypeNow
Sep 3, 2026
28d ago
144
NEUTRAL ★ 2/10
$286.26 $280.76▼ −1.92%▼ −0.77%$267.67 (−6.49%)
Aug 18, 2026
6w ago
144
NEUTRAL ★ 2/10
$278.50 $279.32▲ +0.29%▲ +0.50%$267.67 (−3.89%)
Aug 4, 2026
8w ago
144
NEUTRAL ★ 2/10
$273.45 $273.87▲ +0.16%▲ +0.25%$267.67 (−2.11%)
Jul 9, 2026
12w ago
3
NEUTRAL ★ 2/10
$293.46 $283.82▼ −3.28%▼ −2.72%$267.67 (−8.79%)
May 13, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$300.42 $291.28▼ −3.04%▼ −1.88%$267.67 (−10.90%)
May 6, 2026
21w ago
Court Ruling
NEUTRAL ★ 2/10
$281.98 $300.71▲ +6.64%▲ +5.49%$267.67 (−5.07%)
Apr 30, 2026
22w ago
8-K
BULLISH ★ 7/10
$290.33 $283.65▼ −2.30%▼ −4.03%$267.67 (−7.80%)
Apr 24, 2026
23w ago
Court Ruling
NEUTRAL ★ 3/10
$275.24 $290.58▲ +5.57%▲ +4.67%$267.67 (−2.75%)
Mar 13, 2026
28w ago
DEFA14A
NEUTRAL ★ 3/10
$268.31 $261.49▼ −2.54%▼ −0.50%$267.67 (−0.24%)
Feb 27, 2026
31w ago
8-K
NEUTRAL ★ 4/10
$289.40 $271.04▼ −6.34%▼ −4.36%$267.67 (−7.51%)
Showing 10 of 10

US Market Status

Market Open — Closes in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access